These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2102 related articles for article (PubMed ID: 27627752)

  • 21. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Miere A; Querques G; Semoun O; Amoroso F; Zambrowski O; Chapron T; Capuano V; Souied EH
    Retina; 2017 Oct; 37(10):1873-1879. PubMed ID: 28079756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodal imaging of early stage 1 type 3 neovascularization with simultaneous eye-tracked spectral-domain optical coherence tomography and high-speed real-time angiography.
    Querques G; Souied EH; Freund KB
    Retina; 2013 Oct; 33(9):1881-7. PubMed ID: 23644560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multilayered pigment epithelial detachment in neovascular age-related macular degeneration.
    Rahimy E; Freund KB; Larsen M; Spaide RF; Costa RA; Hoang Q; Christakopoulos C; Munch IC; Sarraf D
    Retina; 2014 Jul; 34(7):1289-95. PubMed ID: 24675391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
    Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
    Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration.
    Giansanti F; Bacherini D; Giacomelli G; Virgili G; Finocchio L; Fiore T; Vannozzi L; Menchini U
    Eur J Ophthalmol; 2014; 24(3):402-8. PubMed ID: 24242217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPATIAL PATTERN OF RETINAL PIGMENT EPITHELIUM TEAR DEVELOPMENT AND PROGRESSION AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Fukui T; Ishikawa K; Shiose S; Kano K; Mori K; Notomi S; Sonoda KH
    Retin Cases Brief Rep; 2024 May; 18(3):371-377. PubMed ID: 36730109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Invernizzi A; Nguyen V; Arnold J; Young S; Barthelmes D; Gillies MC
    Ophthalmology; 2018 Feb; 125(2):237-244. PubMed ID: 28993010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Cho HJ; Kim HS; Yoo SG; Han JI; Lew YJ; Cho SW; Lee TG; Kim JW
    Retina; 2016 Oct; 36(10):1851-9. PubMed ID: 27074658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
    Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
    Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TYPE 3 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
    Kuehlewein L; Dansingani KK; de Carlo TE; Bonini Filho MA; Iafe NA; Lenis TL; Freund KB; Waheed NK; Duker JS; Sadda SR; Sarraf D
    Retina; 2015 Nov; 35(11):2229-35. PubMed ID: 26502007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion.
    Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S
    Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
    Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.
    Schütze C; Wedl M; Baumann B; Pircher M; Hitzenberger CK; Schmidt-Erfurth U
    Am J Ophthalmol; 2015 Jun; 159(6):1100-1114.e1. PubMed ID: 25769245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of the hyperautofluorescent ring associated with choroidal neovascularisation in eyes undergoing anti-VEGF therapy for wet age-related macular degeneration.
    Camacho N; Barteselli G; Nezgoda JT; El-Emam S; Cheng L; Bartsch DU; Freeman WR
    Br J Ophthalmol; 2015 Sep; 99(9):1277-83. PubMed ID: 25777818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The factors associated with retinal pigment epithelium tear development in the early phase after treatment initiation for age-related macular degeneration.
    Shiose S; Notomi S; Hashimoto S; Nagata J; Fukuda Y; Kano K; Ishikawa K; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3171-3180. PubMed ID: 38713397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.
    Ehlers JP; Zahid R; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Le TK; Lunasco L; Hu M; Srivastava SK
    Ophthalmol Retina; 2021 Dec; 5(12):1204-1213. PubMed ID: 33640493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 106.